Roche and Illumina partner to broaden patient access to genomic testing
- Partnership to leverage Illumina?s extensive decentralised installed base with Roche?s expertise in assay development and to provide broad access to clinical oncology next-generation sequencing
- Comprehensive genomic testing improves clinical decision making by genomically defining a patient?s unique cancer and matching optimal treatment
- Collaboration agreement builds upon Roche?s sequencing strategy to accelerate clinical research, streamline workflows and expand assay menus
- In addition, decentralised test expands the reach of Foundation Medicine platform for data and clinical decision support to help patients receive optimal cancer therapy